Prospective comparison of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma

详细信息    查看全文

• 作者：Christina Pfannenberg ; Philip Aschoff ; S ; ra Schanz ; Susanne M. Eschmann ; Christian Plathow ; Thomas K. Eigentler ; Claus Garbe ; Klaus Brechtel ; Reinhard Vonthein ; Rol ; Bares ; et al.
• 关键词：Melanoma ; Staging ; Positron emission tomography/computed tomography ; Whole-body magnetic resonance imaging
• 刊名：European Journal of Cancer
• 出版年：2007
• 出版时间：February 2007
• 年：2007
• 卷：43
• 期：3
• 页码：557-564
• 全文大小：419 K

文摘

The aim of our study was to compare the overall and site-based accuracy and impact on patient management of positron emission tomography/computed tomography (PET/CT) and whole-body (wb) magnetic resonance imaging (MRI) in staging of advanced melanoma. In a prospective blinded study, 64 patients with American Joint Committee on Cancer (AJCC) stage III/IV melanoma underwent ¹⁸F-fluorodeoxyglucose PET/CT and wbMRI. In total 420 lesions were evaluated. The overall accuracy of PET/CT was 86.7 % compared to 78.8 % for wbMRI (P = 0.0007). PET/CT was significantly more accurate in N-staging and detecting of skin and subcutaneous metastases, whereas wbMRI was more sensitive in detecting liver, bone and brain metastases. WbMRI was less sensitive but more specific than PET/CT in classifying pulmonary lesions. In 41 patients (64 % ) whole-body imaging caused changes of treatment. Whole-body staging of patients with advanced melanoma is most accurate by combining wbPET/CT and organ-specific wbMRI including a brain, liver and bone marrow protocol.